CompletedPHASE1, PHASE2NCT05010577
Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection
Studying Cystic fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BiomX, Inc.
- Principal Investigator
- Urania Rappo, MDBiomX, Inc.
- Intervention
- BX004-A(drug)
- Enrollment
- 43 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2024
Study locations (28)
- The University of Alabama at Birmingham, Birmingham, Alabama, United States
- Providence Alaska Medical Center, Anchorage, Alaska, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Yale University, New Haven, Connecticut, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- University of Florida, Gainesville, Florida, United States
- Joe DiMaggio Children's Hospital, Hollywood, Florida, United States
- Central Florida Pulmonary Group, Orlando, Florida, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- New York Medical College, Valhalla, New York, United States
- Cincinnati Children's Hospital, Cincinnati, Ohio, United States
- University Hospitals Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- +13 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05010577 on ClinicalTrials.govOther trials for Cystic fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT04530383Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel FunctionUniversity of Kansas Medical Center
- RECRUITINGPHASE2NCT07450547Phase 2 Study to Assess the Safety and Efficacy of ANG003Anagram Therapeutics, Inc.
- RECRUITINGPHASE1NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNANCT07436351ACT With CF Self-Help ToolkitThomas Jefferson University
- RECRUITINGNANCT07314229Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-IvacaftorUniversity Hospital, Lille
- RECRUITINGNCT07083557Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)Bettina Mittendorfer
- RECRUITINGNCT07369414Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at HomeResearch Center Borstel
- RECRUITINGNCT07505797ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)iSono Health, Inc.